I’m assuming CYDY is waiting for data from additional patients before releasing the percentage the CTC and tumor size decreased. I like usage of the word, “significant”, to describe the decrease, but potential investors may want more. Also, it’s only one patient but I’m excited that the CTC was reduced in the first patient dosed and that the receptor occupancy test is helping to identify those who leronlimab will work for.

This will no doubt boost enrollment in the trial and move the mTNBC trial forward. Lets hope that additional patients have similar results so we can get his drug to this who need it and finally see a return on our investment.